Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CanQuit RCT
NCT06832085Phase 4Recruiting
- Sponsor
- University of Ottawa Heart Institute
- Start
- Apr 2025
- Primary completion
- Apr 2027
- Modality
- Transdermal Patches, Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of nicotine patch, cytisinicline and varenicline + nicotine patch in Tobacco Use Disorder (TUD) (4 arms), sponsored by University of Ottawa Heart Institute. Primary endpoint: Participant's Smoking Status at 6 months. Started Apr 2025; status: recruiting.
02
Drugs
nicotine patchcytisiniclinevarenicline + nicotine patch
03
Conditions
Tobacco Use Disorder (TUD)
Beyond the preview
Go deeper on NCT06832085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06832085.